ISSN: 1859 - 2872
Ghép tế bào gốc tạo máu đồng loài kết hợp sử dụng kỹ thuật chiếu xạ toàn thân trong phác đồ điều kiện hoá để điều trị bệnh bạch cầu cấp dòng lympho
Main Article Content
Keywords
Chiếu xạ toàn thân, Bạch cầu cấp dòng lympho, ghép tế bào gốc tạo máu đồng loài
Tóm tắt
Chiếu xạ toàn thân (Total Body Irradiation - TBI) là kỹ thuật cao được sử dụng trong điều kiện hoá ở bệnh nhân (BN) dị ghép tế bào gốc tạo máu (TBGTM). Việc sử dụng TBI trong dị ghép TBGTM đã được triển khai từ sớm tại các quốc gia trên thế giới trong điều trị các bệnh lý huyết học lành tính và ác tính. Lần đầu tiên tại Việt Nam, kỹ thuật TBI được áp dụng vào điều kiện hoá trong ghép TBGTM bạch cầu cấp dòng lympho. Kết luận: Chúng tôi bước đầu thực hiện báo cáo hai trường hợp lâm sàng là những người bệnh bạch cầu cấp dòng lympho nguy cơ cao được ghép TBGTM sử dụng phác đồ điều kiện hoá có TBI.
Article Details
Các tài liệu tham khảo
1. Marks DI, Forman SJ, Blume KG et al (2006) A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 12: 438-53.
2. Litzow MR, Perez WS, Klein JP et al (2002) Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan - cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119: 1115-24.
3. Jamieson CHM, Amylon MD, Wong RM, Blume KG (2003) Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: A 15-year experience. Experimental Hematology 3: 98-6.
4. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG) (2009) Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: A systematic review and meta-analysis. Br J Haematol 145: 376-388.
5. Davies SM, Ramsay NK, Klein JP et al (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18: 340-347.
6. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S (2003) Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 32: 543-548.
7. Wall DA, Chan KW, Nieder ML et al (2008) Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing 15. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 14: 137-180.
8. Ferry C, Gemayel G, Rocha V et al (2007) Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant 40: 219-224.
9. Cohen A, Rovelli A, Merlo DF et al (2007) Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: An EBMT Late Effects Working Party Study. J Clin Oncol 25: 2449-2454.
10. Bhatia S, Robison LL, Francisco L et al (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: Report from the Bone Marrow Transplant Survivor Study. Blood 105: 4215-4222.
11. Socie G, Curtis RE, Deeg HJ et al (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348-357.
12. Russell JA, Tran HT, Quinlan D et al (2002) Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8: 468-476.
13. Styczynski J, Tallamy B, Waxman I et al (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 46: 790-799.
2. Litzow MR, Perez WS, Klein JP et al (2002) Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan - cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119: 1115-24.
3. Jamieson CHM, Amylon MD, Wong RM, Blume KG (2003) Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: A 15-year experience. Experimental Hematology 3: 98-6.
4. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG) (2009) Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: A systematic review and meta-analysis. Br J Haematol 145: 376-388.
5. Davies SM, Ramsay NK, Klein JP et al (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18: 340-347.
6. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S (2003) Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 32: 543-548.
7. Wall DA, Chan KW, Nieder ML et al (2008) Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing 15. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 14: 137-180.
8. Ferry C, Gemayel G, Rocha V et al (2007) Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant 40: 219-224.
9. Cohen A, Rovelli A, Merlo DF et al (2007) Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: An EBMT Late Effects Working Party Study. J Clin Oncol 25: 2449-2454.
10. Bhatia S, Robison LL, Francisco L et al (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: Report from the Bone Marrow Transplant Survivor Study. Blood 105: 4215-4222.
11. Socie G, Curtis RE, Deeg HJ et al (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348-357.
12. Russell JA, Tran HT, Quinlan D et al (2002) Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8: 468-476.
13. Styczynski J, Tallamy B, Waxman I et al (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 46: 790-799.
Article Sidebar
Đã đăng
Feb 5, 2024
Số tạp chí
Chuyên mục
Articles
Trích dẫn bài viết này
DũngP. C., Dương Đỗ T. T., QuangN. T., MẫnH. V., NhungP. T. T., PhươngN. T. M., KiênN. X., TrungP. Q., & DươngT. Ánh. (2024). Ghép tế bào gốc tạo máu đồng loài kết hợp sử dụng kỹ thuật chiếu xạ toàn thân trong phác đồ điều kiện hoá để điều trị bệnh bạch cầu cấp dòng lympho . Journal of 108 - Clinical Medicine and Phamarcy, 19(1). https://doi.org/10.52389/ydls.v19i1.2115